Drug Trial Radar · NCT05138796
A Pharmacokinetic Study of TP-05 in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Aug 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
67
Actual
Start
May 6, 2021
Primary completion
Mar 25, 2022
Study completion Jul 25, 2022
Sponsor
- Lead sponsor
- Tarsus Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 1, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 59 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Phase 1, Randomized, Double-Blind, Single- and Multiple-Ascending Dose Study Evaluating the Safety, Tolerability, Food-Effect and Pharmacokinetics of TP-05 in Healthy Subjects
Conditions
- Healthy
Interventions
TP-05 (lotilaner oral capsules)Drug
TP-05 (lotilaner oral capsules)
PlaceboDrug
Placebo to match TP-05 (lotilaner oral capsules)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment emergent adverse events (TEAEs)Time frame: up to 151 days
- Clinically significant changes from Baseline chemistry laboratory testsTime frame: up to 151 days
- Clinically significant changes from Baseline hematology laboratory testsTime frame: up to 151 days
- Clinically significant changes from Baseline general appearanceTime frame: up to 151 days
- Clinically significant changes from Baseline physical examination of head, ears, nose, and throatTime frame: up to 151 days
- Clinically significant changes from Baseline physical examination of neck (thyroid)Time frame: up to 151 days
- Clinically significant changes from Baseline physical examination of respiratory systemTime frame: up to 151 days
- Clinically significant changes from Baseline physical examination of cardiovascular systemTime frame: up to 151 days
- Clinically significant changes from Baseline physical examination of gastrointestinal systemTime frame: up to 151 days
- Clinically significant changes from Baseline physical examination of neurological systemTime frame: up to 151 days
- Clinically significant changes from Baseline physical examination of musculoskeletal system (extremities)Time frame: up to 151 days
- Clinically significant changes from Baseline physical examination of skinTime frame: up to 151 days
- Clinically significant changes from Baseline vital signsTime frame: up to 151 days
- Clinically significant changes from Baseline vital signs (temperature [degrees Celsius])Time frame: up to 151 days
- Clinically significant changes from Baseline vital signs (pulse rate [beats per minute])Time frame: up to 151 days
- Clinically significant changes from Baseline vital signs (respiration rate [breaths per minute])Time frame: up to 151 days
- Clinically significant changes from Baseline vital signs (systolic and diastolic blood pressure [mmHg])Time frame: up to 151 days
- Clinically significant changes from Baseline electrocardiograms (ECGs)Time frame: up to 151 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Altasciences
Overland Park, Kansas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.